<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124417">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955473</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200637-001</org_study_id>
    <nct_id>NCT01955473</nct_id>
  </id_info>
  <brief_title>Japanese Phase 1 Trial of Sym004 in Solid Tumors</brief_title>
  <official_title>A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose-escalation trial to assess the safety and tolerability
      of Sym004, administered weekly or biweekly as monotherapy in Japanese subjects with advanced
      solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose Limiting Toxicity as determined in Part-A</measure>
    <time_frame>Up to Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>Up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Sym004:  Area under curve (AUC), Half-life (t1/2 ), Clearance (CL), Volume of distribution at the elimination phase (Vz ), Maximum concentration (Cmax ), Trough concentration (Ctrough), Time to reach Cmax (tmax )</measure>
    <time_frame>Up to 8 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>Week 7 and thereafter every 6 weeks, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>Week 7 and thereafter every 6 weeks until the first date of objectively documented recurrent or progressive disease, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Week 7 and thereafter every 6 weeks, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease control</measure>
    <time_frame>Week 7 and thereafter every 6 weeks until the first date of objectively documented recurrent or progressive disease, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time from enrollment until the date of  objectively documented disease progression, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>Time from enrollment until the date of objectively documented disease progression or death, up to 4 weeks after the last Sym004 administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in anti-drug antibody (ADA) titer at Weeks 1 and 5</measure>
    <time_frame>Baseline, Weeks 1 and 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidermal  growth factor receptor levels in skin tissues</measure>
    <time_frame>Weeks 1 and 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sym004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym004</intervention_name>
    <description>Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.</description>
    <arm_group_label>Sym004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female subjects aged greater than or equal to 20 years at the time
             of informed consent signature

          -  Histologically or cytologically confirmed cancer

          -  Refractory  or  recurrent  advanced  late  stage  solid tumors  without  available
             therapeutic  options  which  are likely  to  provide  patient  benefit  (failure
             and/or intolerance to standard anti-cancer therapy)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Written  informed  consent  given  before  any  trial-related activities are carried
             out

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Subjects with symptomatic brain metastases

          -  Subjects who received total resection or irradiation of the target lesion

          -  Received any  of  the  following  medications within 4 weeks  before  the  first
             administration  of  Sym004  at Week 1: cytotoxic  or  cytostatic  anti-cancer
             therapy, antibody  therapy,  tyrosine  kinase  inhibitors,  and  any investigational
             agent

          -  Received vaccine therapy  as  anticancer  treatment within 12 weeks  before  the
             first  administration  of Sym004 at Week 1

          -  Diarrhea of greater than Grade 1 according to  National Cancer Institute-Common
             Terminology  Criteria  for  Adverse Events (NCI-CTCAE) version 4.03 (v4.03)

          -  Skin  manifestation of greater than Grade 1  according  to  NCI-CTCAE (v4.03)

          -  Magnesium of less than 0.9 milligram per deciliter (mg/dL)

          -  Abnormal organ or bone marrow function as defined in the protocol

          -  Received immunosuppressive agents (including systemic corticosteroids used at doses
             above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks
             before the first administration of Sym004 at Week 1

          -  Active severe infection, any other concurrent disease or  medical  conditions  that
             are  deemed  to  interfere  with the conduct of the trial as judged by the
             Investigator

          -  Known human immunodeficiency virus  (HIV) positive, active Hepatitis B or C, or
             uncontrolled allergic conditions or allergy to Sym004 or its components

          -  Clinically  significant  cardiac disease or concurrent,  uncontrolled  medical
             condition

          -  Known  previous  Grade 3 to 4  infusion-related reactions, according  to  NCI-CTCAE
             (v4.03),  with chimeric monoclonal antibodies

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center located in</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Sym004</keyword>
  <keyword>Phase 1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
